Proye Pauline, Gondran-Tellier Bastien, Michel Floriane, Bensalah Karim, Bigot Pierre, Audenet François, Champy Cécile, Merlin Pierre, Bruyere Franck, Roupret Morgan, Marcq Gautier, Surlemont Louis, Parier Bastien, Waeckel Thibaut, Michel Constance, Branger Nicolas, Tricart Thibault, Sarrazin Clément, Patard Jean-Jacques, Vallée Maxime, Beauval Jean-Baptiste, Fontenil Alexis, Mallet Richard, Guillotreau Julien, Panthier Frédéric, Belas Olivier, Vergie Stéphane De, Clerc Quentin-Côme Le, Doumerc Nicolas, Taha Fayek, Rouget Benjamin, Gimel Pierre, Bernhard Jean-Christophe, Boissier Romain
Aix-Marseille Université, Service de Chirurgie Urologique et de Transplantation rénale, CHU Conception, APHM, Marseille, France.
Département d'urologie, CHU de Rennes, Rennes, France.
Eur Urol Open Sci. 2025 Feb 15;73:60-67. doi: 10.1016/j.euros.2025.01.016. eCollection 2025 Mar.
A renal mass biopsy (RMB) is not systematically recommended before surgical excision of a renal mass, although it has demonstrated elevated accuracy in determining renal masses with low morbidity. Our aim was to determine the diagnostic accuracy of an RMB, the clinical and tumoral factors associated with RMB practice, and the impact of an RMB on renal cell carcinoma management in a contemporary prospective national registry-UroCCR (2010-2021).
We identified all patients with a single renal mass (pT1-4 N0-2 M0 or benign) who were treated surgically and stratified them according to the performance of a prior RMB. Patients treated by active surveillance, percutaneous ablative treatment, or stereotaxic radiotherapy were excluded. Diagnostic accuracy of an RMB was determined in the RMB group. Clinical and tumoral factors associated with the practice of RMBs were analyzed using logistic regression.
In total, 9283 patients were included, who presented 1594 tumors (17%) with a prior RMB. RMBs were 92.4% contributive. The correlation between an RMB and excision in the determination of benign/malignant disease, histological subtype, and grade are, respectively, 96.9%, 86.4%, and 52.6%. The impact of an RMB versus no prior RMB was determined according to the rate of surgical excision for benign lesion and the rate of partial nephrectomy (63.9% vs 57.8%; < 0.001).
An RMB is performed rarely when its diagnostic performance is high. A prior RMB significantly changes the management of localized renal masses, with fewer surgical procedures for benign renal masses and conservative treatment in a higher proportion of patients.
In a large and contemporary registry, we demonstrated that a renal mass biopsy has excellent diagnostic accuracy, significantly reduces renal surgery for benign masses and low-grade/stage renal cell carcinoma, and increases conservative surgical excision.
肾肿物活检(RMB)在肾肿物手术切除前并非常规推荐检查,尽管其在确定肾肿物方面准确性较高且并发症发生率较低。我们的目的是在当代前瞻性全国性登记数据库-UroCCR(2010 - 2021年)中,确定RMB的诊断准确性、与RMB操作相关的临床和肿瘤因素,以及RMB对肾细胞癌治疗的影响。
我们纳入了所有接受手术治疗的单发肾肿物患者(pT1 - 4 N0 - 2 M0或良性),并根据是否进行过RMB将他们分层。接受主动监测、经皮消融治疗或立体定向放疗的患者被排除。在RMB组中确定RMB的诊断准确性。使用逻辑回归分析与RMB操作相关的临床和肿瘤因素。
总共纳入9283例患者,其中1594例肿瘤(17%)患者进行过RMB。RMB的贡献率为92.4%。在确定良性/恶性疾病、组织学亚型和分级方面,RMB与切除之间的相关性分别为96.9%、86.4%和52.6%。根据良性病变的手术切除率和部分肾切除术的发生率(63.9%对57.8%;P < 0.001),确定了进行RMB与未进行RMB的影响。
当RMB的诊断性能较高时,其实施频率较低。先前进行的RMB显著改变了局限性肾肿物的治疗方式,良性肾肿物的手术操作减少,更多患者接受保守治疗。
在一个大型当代登记数据库中,我们证明肾肿物活检具有出色的诊断准确性,显著减少了良性肿物和低级别/低分期肾细胞癌的肾手术,并增加了保守性手术切除。